Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025)

X4 Pharmaceuticals' Net Margin history spans 6 years, with the latest figure at 931.66% for Q4 2025.

  • For Q4 2025, Net Margin rose 184526.0% year-over-year to 931.66%; the TTM value through Dec 2025 reached 225.55%, up 123905.0%, while the annual FY2025 figure was 225.55%, 124101.0% up from the prior year.
  • Net Margin reached 931.66% in Q4 2025 per XFOR's latest filing, up from 1689.24% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 16133.75% in Q2 2024 to a low of 6552.86% in Q3 2024.
  • Average Net Margin over 4 years is 1225.16%, with a median of 1074.8% recorded in 2022.
  • The largest YoY upside for Net Margin was 486362bps in 2025 against a maximum downside of -1743841bps in 2025.
  • A 4-year view of Net Margin shows it stood at 2544.06% in 2022, then fell by -15bps to 2165.92% in 2023, then tumbled by -228bps to 2776.92% in 2024, then soared by 66bps to 931.66% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Net Margin are 931.66% (Q4 2025), 1689.24% (Q3 2025), and 1304.66% (Q2 2025).